Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Wee ZN, Yatim SMJM, Kohlabauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DSB, Tan EY, Yu Q.

Nat Commun. 2015 Nov 20;6:10054. doi: 10.1038/ncomms10054. No abstract available.

PMID:
26585835
2.

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q.

Nat Commun. 2015 Oct 27;6:8746. doi: 10.1038/ncomms9746. Erratum in: Nat Commun. 2015;6:10054. Yi, Bao [Corrected to Bao, Yi].

3.

EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.

Wee ZN, Li Z, Lee PL, Lee ST, Lim YP, Yu Q.

Cell Rep. 2014 Jul 10;8(1):204-16. doi: 10.1016/j.celrep.2014.05.045. Epub 2014 Jun 19.

4.

PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.

Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q.

Cancer Discov. 2013 Oct;3(10):1156-71. doi: 10.1158/2159-8290.CD-12-0595. Epub 2013 Jul 25.

5.

The distal carboxyl terminal of rat NR3B subunit regulates NR1-1a/NR3B and NR1-2a/NR3B surface trafficking.

Wee KS, Wee ZN, Chow NB, Low CM.

Neurochem Int. 2010 Sep;57(2):97-101. doi: 10.1016/j.neuint.2010.05.003. Epub 2010 May 11.

PMID:
20466026

Supplemental Content

Support Center